Adage Capital Partners GP LLC Dissolves Share Stake In Moderna, Takes In Gilead Sciences!
Germany requests 5% of EU supply of remdesivir
Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the...
I also wrote on the huge upside potential of Gilead when they acquired Immunomedics for $21 billion.
The acquisition expands Gilead's portfolio of treatments for various types of cancer.
On 9/10/2020 Oppenheimer Brokerage Boosted Price Target to Outperform from...
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
The deal with Immunomedics provides Gilead (GILD) with Trodelvy, an antibody drug for advanced triple-negative breast cancer. The drug was given accelerated FDA approval in April. (Source CNN Business).
Sell on 1 hour chart
Buy on 7h chart
Sell on 3 day chart, but a trend...
📍 The effect of Remdesivir...
The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in.
Compare the following two diagrams:
June 29 (Reuters) - Gilead Sciences Inc GILD on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
Remdesivir is expected to be in high demand as one of the only treatments shown to alter the course of COVID-19. After...
It is trading below RSI 50 and 50SMA which put the stock in bearish. After fast dropped down, it may pull back to $75. However, if there will be no any good news will support the stock most likely it will continue descending.
If you like my charts useful, please leave me "like"
U.S. FDA approved Gilead Sciences Inc.’s experimental antiviral drug, remdesivir, for use as it’s showing good signs of helping hospitalised patients recover more quickly from Corona Virus.
From a Trend Analysis perspective - price action has been very choppy with lots of buying and selling in an almost Up-trending consolidation.
We expect Gilead to push...